New Non-Invasive Cardiac Monitoring System Gains Funding
A new device aims to assess heart function without invasive procedures for patients undergoing cardiac evaluation.
Updated on Oct. 26, 2026 in Heart Disease
Live Poll
Should investors prioritize funding medical technologies that offer non-invasive alternatives to traditional procedures?
Valencia-based medical device developer Sensydia has secured over $6 million in new funding to support its Cardiac Performance System. This capital will help the company pursue FDA authorization for its non-invasive technology designed to assess cardiac function.
Why it matters
The funding accelerates efforts to bring a device to market that provides pulmonary pressure assessments without the need for invasive catheterization. This development represents a potential shift in how cardiac patients in Valencia and beyond may be monitored for heart health.
Sensydia secured over $6 million in funding to initiate its ACOUSTIC-1 study. This research will evaluate a diagnostic system designed to assess pulmonary pressure and cardiac function without invasive catheterization.
The players
Sensydia
A Valencia-based medical technology company focused on developing non-invasive tools for monitoring cardiac performance.
Colle Capital Partners
An investment firm that led the recent funding round for Sensydia.
Orlando Health Ventures
The strategic investment arm of a health system that provided support for the funding round.
The details
The Cardiac Performance System employs artificial intelligence algorithms to process acoustic and electrical signals from the heart. By analyzing these biomarkers, the technology aims to estimate cardiac function non-invasively, providing clinicians with data that historically required catheter-based procedures. The device already has a dedicated CPT code in place, which facilitates the path toward integration into routine clinical practice.
Timeline
October 26, 2026: The funding round for Sensydia was announced.
Health Landscape
The Cardiac Performance System seeks to modernize diagnostic monitoring by offering a non-invasive alternative to the standard clinical pulmonary artery catheter. This technology represents a broader move toward using machine learning to derive clinical insights from non-invasive acoustic and electrical signals.
While this technology is not yet commercially available, its progress toward FDA authorization may eventually change how heart-function monitoring is performed in clinical settings. Patients who currently undergo invasive cardiac assessments should discuss potential future diagnostic alternatives with their cardiologist.
The takeaway
The development of non-invasive tools for monitoring cardiac health could eventually reduce the need for more complex procedures. If you have concerns about your current heart-monitoring regimen, consult with your physician to understand what diagnostic options are appropriate for your specific condition.
Further reading
Learn more about the latest innovations in Heart Disease management and diagnostics.
Source note: This article includes information reported by Los Angeles Times.
Live Poll
Should investors prioritize funding medical technologies that offer non-invasive alternatives to traditional procedures?
